Histamine: a new immunomodulatory player in the neuron-glia crosstalk by Sandra M. Rocha et al.
CELLULAR NEUROSCIENCE
PERSPECTIVE ARTICLE
published: 30 April 2014
doi: 10.3389/fncel.2014.00120
Histamine: a new immunomodulatory player in the
neuron-glia crosstalk
Sandra M. Rocha†, Joel Pires†, Marta Esteves, Graça Baltazar and Liliana Bernardino*
Health Sciences Research Centre, Faculty of Health Sciences, University of Beira Interior, Covilhã, Portugal
Edited by:
Raquel Ferreira, University of
Southern California, USA
Reviewed by:
Fabio Blandini, C. Mondino National
Institute of Neurology Foundation,
Italy
Stefano Pluchino, University of
Cambridge, UK
*Correspondence:
Liliana Bernardino, Health Sciences
Research Centre, Faculty of Health
Sciences, University of Beira
Interior, Av. Infante D. Henrique,
6200-506 Covilhã, Portugal
e-mail: libernardino@gmail.com
†These authors have contributed
equally to this work.
Histamine is an amine acting as a major peripheral inflammatory mediator. In the brain,
histamine was initially viewed as a neurotransmitter, but new evidences support its
involvement in the modulation of innate immune responses. Recently, we showed that
histamine modulates microglial migration and cytokine release. Its pleiotropic actions,
ranging from neurotransmission to inflammation, highlight histamine as a key player
in a vast array of brain physiologic activities and also in the pathogenesis of several
neurodegenerative diseases. Herein, we emphasize the role of histamine as a modulator
of brain immune reactions, either by acting on invading peripheral immune cells and/or
on resident microglial cells. We also unveil the putative involvement of histamine in the
microglial-neuronal communication. We first show that histamine modulates the release
of inflammatory mediators, namely nitric oxide, by microglia cells. Consequently, the
microglia secretome released upon histamine stimulation fosters dopaminergic neuronal
death. These data may reveal important new pharmacological applications on the use
histamine and antihistamines, particularly in the context of Parkinson’s disease.
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HISTAMINE: GENERAL ASPECTS
Histamine is an endogenous biogenic amine synthesized from L-
histidine through the catalytic activity of the enzyme histidine
decarboxylase. In peripheral tissues, mast cells and basophils are
the main sources of histamine. Other sources of histamine include
gastric enterochromaffin-like cells, platelets and neutrophils. In
the adult brain, histamine is produced by neurons, mast and
microglia cells (Katoh et al., 2001; Haas et al., 2008). Histamine
exerts its functions through the activation of four distinct recep-
tors belonging to the rhodopsin-like family of G protein-coupled
receptors (GPCRs): H1 receptor (H1R), H2 receptor (H2R), H3
receptor (H3R) and H4 receptor (H4R). These functions range
from the modulation of the allergic reactions and behavioral
state and reinforcement (H1R); regulation of heart and gastric
acid secretion, learning and memory (H2R); neurotransmitter
release, cognition and memory (H3R); and chemotactic effects
(H4R), among others (Haas et al., 2008; Molina-Hernández et al.,
2012). Three (H1R, H2R and H3R) out of the four histamine
receptors are widely expressed in the nervous system (Haas
et al., 2008; Leurs et al., 2009). However, the expression of
H4R has remained controversial. Several groups could not detect
H4R mRNA, while other labs reported their expression in the
amygdala, cerebellum, hippocampus, caudate nucleus, substantia
nigra (SN), thalamus and hypothalamus (Strakhova et al., 2009).
Recently, we found that all four types of histamine receptors are
expressed by N9 microglia cell line and cortical-derived microglial
cells (Ferreira et al., 2012). The levels of histamine and its
metabolites have been evaluated in physiologic and pathologic
brain conditions. The concentrations of histamine found in the
cerebrospinal fluid (CSF) and parenchyma of the intact brain are
very low, at the nanomolar range (Croyal et al., 2011). Impor-
tantly, circulating levels of histamine and histaminergic inner-
vations are increased following brain injury and degeneration
or infection, suggesting that histamine may have an important
role in modulating neuronal survival (Anichtchik et al., 2000a;
Figure 1).
HISTAMINE: A PERIPHERAL IMMUNE MEDIATOR
Several brain injuries and inflammatory conditions are associated
with increased levels of circulating histamine, both in the blood
and in the CSF, leading to blood brain barrier permeability
(BBB). Histamine may thus modulate the expression of several
inflammatory molecules by peripheral immune cells, including,
macrophages, monocytes, T and B lymphocytes (Jutel et al.,
2006). In these conditions, activated peripheral immune cells may
cross the BBB and exert its immunomodulatory activities in the
brain parenchyma (Figure 1).
Histamine may play a dual role in the inflammatory response
driven by macrophages. In fact, it was shown that histamine
induced interleukin (IL)-6 release by macrophages via H1R
activation (Marone et al., 2001), whereas inhibited chemotaxis,
phagocytosis, Tumor Necrosis Factor (TNF)-α, IL-12 and super-
oxide anion production via H2R (Azuma et al., 2001). Histamine
can also stimulate monocytes, but not macrophages, to express
monocyte chemoattractant protein (MCP)-1 and its receptors
CCR2-A and -B via H2R receptor activation (Kimura et al., 2004).
Gschwandtner et al. showed that histamine down-regulated IL-27
production by human monocytes through H2R and H4R, but did
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FIGURE 1 | Integrative scheme of the effects driven by histamine in
peripheral and innate immune cells that ultimately may interfere with
neuronal survival. In the healthy brain the “bulk” concentration of
histamine is very low. Upon brain injury, degeneration or infection, the
inflammatory response may trigger degranulation of mast cells, leading to a
massive release of histamine in the blood and in the cerebrospinal fluid,
leading to an increase of blood brain barrier (BBB) permeability. In this
context, peripheral immune cells may cross the BBB and invade the brain
parenchyma. Increased levels of histamine may activate distinct histamine
receptors at peripheral (macrophages, monocytes, T and B lymphocytes)
and innate immune cells (microglia) leading to the release of pro- or
anti-inflammatory cytokines, chemokines, reactive oxygen species (ROS)
and nitric oxide (NO). Histamine may thus have a dual role in the modulation
of neuronal survival in the context of several neurodegenerative diseases,
including Multiple Sclerosis (MS), Alzheimer’s disease (AD) and Parkinson’s
disease (PD), depending on the type of histamine receptor activated,
signaling pathways involved and factors released.
not influence IL-6, IL-10 and TNF-α production (Gschwandtner
et al., 2012). Lymphocytes are predominantly involved in adap-
tive immunity and play a key role in the pathogenesis of brain
disorders associated with inflammation, such as multiple sclerosis
(MS). T cells express histamine receptors being thus respon-
sive to histamine stimulation. For instance, histamine enhances
TH1-type activity through H1R, whereas both TH1- and TH2-
type responses are negatively regulated by H2R (Jutel et al.,
2001). The impact of histamine on immunoglobulin secretion
by B cells depends on the requirement of T cells (Ferstl et al.,
2012).
In conclusion, the effects of histamine on peripheral immune
cells are often contradictory leading either to the stimulation or
inhibition of inflammatory processes. This can be due to the type,
affinity and abundance of each receptor subtype and consequently
to the involvement of distinct downstream regulatory pathways,
to the levels of histamine and to the cell types used in each study.
Even if comprehension regarding the regulatory pathways acti-
vated by each histamine receptor is warranted, there are already
several evidences that strengthen the idea that histamine and its
receptor agonists/antagonists are promising targets to modulate
inflammatory conditions.
HISTAMINE: NEWMODULATOR OF MICROGLIAL ACTIVITY
Microglial cells, the resident immune cells in the brain, have the
ability to patrol and protect the parenchyma against brain injuries
and/or infections. In a healthy environment, resting microglia
display low expression levels of inflammatory molecules, but
when activated, microglial cells abandon their ramified surveilling
morphology, become ameboid, phagocytic, migrate to the injured
site and release inflammatory molecules (Polazzi and Monti,
2010). The density and phenotype of microglial cells are region-
specific. In particular, a higher density of microglia in the sub-
stantia nigra pars compact (SNpc) lead several authors to suggest
that microglia play an important role in the pathogenesis of
Parkinson’s disease (PD; Collins et al., 2012). In accordance,
higher numbers of activated microglia were found in the vicinity
of degenerating SNpc dopaminergic neurons of post-mortem PD
brains (Long-Smith et al., 2009). A major unanswered question is
whether microglia activation is a consequence or a cause of nigra
dopaminergic cell loss. Recent studies suggest that neuronal loss
leads to the extracellular release of protein aggregates from neu-
rons causing microglia activation (Hafner-Bratkovicˇ et al., 2012).
On the other hand, a large body of literature also supports the idea
that microglia potentially increase the risk of development and
exacerbation of the neurodegenerative pathology (Phani et al.,
2012).
Microglia release a huge number of inflammatory mediators,
including histamine (Katoh et al., 2001). We have recently shown,
for the first time, that histamine modulates microglial migration
and cytokine release (Ferreira et al., 2012). Histamine, acting via
H4R, increased microglial motility through the involvement of
α5β1 integrins and the p38 MAPK and Akt signaling pathways.
Additionally, histamine also modulated IL-1β release by microglia
(Ferreira et al., 2012). In that sense, histamine may have an
impact in the pathogenesis of brain diseases which are asso-
ciated with inflammatory conditions (Figure 1). Our previous
study was performed using a N9 microglia cell line, but there
is a lack of information regarding the effects of histamine in
microglia cells derived from the SN, a brain region enriched with
microglia and highly susceptible to dopaminergic neuronal loss.
Thus, we evaluated the effects of histamine on the production
of an inflammatory mediator, nitric oxide (NO), by microglial
cells derived from the SN of neonatal rats. We measured the
amount of nitrite (a stable metabolite of NO) released by primary
microglial cells after 24 h of treatment with different histamine
concentrations (1 µM; 10 µM and 100 µM). Lipopolysaccharide
(LPS; 100 ng/mL), a potent stimulator of microglia activation that
causes the release of various inflammatory factors and free radi-
cals, was used as a positive control. Microglial cells, isolated from
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the ventral midbrain of postnatal (P2-3) Wistar rats, were grown
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% Fetal Bovine Serum and 100 U/mL penicillin plus
100 µg/mL streptomycin, as described previously (Saura et al.,
2003). The Griess Assay was used to measure NO production
and values were expressed as percentage of increase with respect
to the untreated cultures (controls set to 100%). We found that
histamine significantly increased NO release (meanH1 = 138.5 ±
11.7; meanH10 = 125.0 ± 9.4; meanH100 = 140.2 ± 5.1, n =
3–15), as compared to control (Figure 2A). Histamine did not
interfere with microglia cell death or proliferation at all con-
centrations tested (data not shown). As expected, 100 ng/ml
LPS increased NO production (meanLPS = 178.4 ± 12.2, n =
16; Figure 2A). Based on these results and on prior studies
reported by our group (Agasse et al., 2008; Bernardino et al.,
2008; Grade et al., 2010; Rosa et al., 2010) and by others
(Wang et al., 1997; Hernández-Angeles et al., 2001; Nicolson
et al., 2002; Tran et al., 2004; Molina-Hernández and Velasco,
2008; Nemeth et al., 2012), we then used 100 µM histamine
in further experiments, a concentration of pathophysiological
relevance.
NO is produced from L-arginine by different isoforms of NOS
and takes part in many normal physiological functions, such
as promoting vasodilation of blood vessels and mediating cell
communication within the brain. In addition to its physiolog-
ical actions, the free radical activity of NO may cause cellu-
lar damage through a phenomenon known as nitrosative stress
(Knott and Bossy-Wetzel, 2009). Since the main inducible enzyme
responsible for NO synthesis in microglia cells is inducible nitric
oxide synthase (iNOS), we then hypothesized that iNOS expres-
sion was also upregulated by histamine. To test this hypothesis,
microglial cells were treated for 24 h with 100 ng/mL LPS or
100 µM histamine, fixed and stained against iNOS (polyclonal
rabbit anti-iNOS; 1:100; BD Transduction Laboratories). Fluo-
rescent images were acquired using a Zeiss inverted microscope
(Axiobserver Z1, Zeiss) and the fluorescence intensity was mea-
sured through ImageJ software (60 cells per condition). The
background fluorescence intensity was always subtracted in order
to quantify the corrected intensity of the iNOS fluorescence in
each condition. The same confocal image acquisition settings
were used in all experiments. As shown the Figures 2B and
2C, both histamine and LPS significantly increased the expres-
sion of iNOS in microglial cells (meanH100 = 232.0 ± 31.8;
meanLPS = 316.6 ± 36; n = 3). This suggests that histamine
could act as a NO-regulating factor by inducing iNOS expression.
Others also showed that histamine stimulates endothelial NO
production and iNOS expression via H1R and nuclear factor
(NF)-kappaB signaling pathway in intimal smooth muscle cells
(Tanimoto et al., 2007). NO has been shown to modify protein
function by nitrosylation and nitrotyrosination, to contribute to
glutamate excitotoxicity, inhibit mitochondrial respiratory com-
plexes, participate in organelle fragmentation, and mobilize zinc
from internal stores (Knott and Bossy-Wetzel, 2009). NO can
react with superoxide radicals to form peroxynitrite radicals
that are short-lived oxidants and highly damaging to neurons.
Mitochondrial injury is prevented by treatment with an iNOS
FIGURE 2 | Histamine induced NO release by microglial cells and
subsequent dopaminergic neuronal death. (A) Histamine at 1 µM (H1),
10 µM (H10) and 100 µM (H100) triggered an increase of NO release by
microglial cells. LPS (100 ng/ml) was used as a positive control. (B) Bargram
shows that histamine increased inducible nitric oxide synthase (iNOS)
expression by microglial cells. (C) Representative fluorescent digital images
of microglial cell cultures treated with 100 µM histamine or 100 ng/ml LPS
and stained against iNOS (red staining). For nuclear labeling, cells
preparations were counterstained with Hoechst (2 µg/mL; blue staining). (D)
The conditioned medium derived from microglial cells pre-treated with
100 µM histamine or 100 ng/mL LPS decreased the numbers of TH+-neurons
(dark gray bars). The conditioned medium pre-treated solely with histamine or
LPS (devoid of microglia-induced soluble factors) did not affect dopaminergic
neuronal survival (light gray bars). Results are expressed as the mean value of
TH+ cells in relation to all nuclei stained with Hoechst. (E) Representative
fluorescence digital images of midbrain neuronal-glial co-cultures treated with
microglia-derived conditioned medium. Green staining: TH+ neurons; red
staining: MAP-2 positive neurons; blue staining: nuclei. Scale bar = 10 µm.
Ctr: control; LPS: 100 ng/mL LPS; H100: 100 µM histamine. Data are
expressed as mean ± SEM. Statistical analysis was performed using one-way
ANOVA with Dunnett’s correction. ** P < 0.01 and *** P < 0.001 as
compared with the untreated control—set to 100%.
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inhibitor, suggesting that iNOS-derived NO is also associated with
the mitochondrial impairment (Choi et al., 2009). NO inhibits
cytochrome c oxidase in competition with oxygen, resulting in
glutamate release and excitotoxicity (Brown and Neher, 2010).
However, the molecular mechanisms involved on the modu-
latory effect of histamine on NO production are unknown.
Nevertheless, it is known that activation of extracellular signal-
regulated kinases, c-Jun N-terminal kinases and p38 MAPK leads
to activation of transcription factors, such as NF-kappaB and
activator protein 1 (AP-1), that are involved in expression of
the iNOS gene, which is followed by the sustained production
of NO by activated microglia (Jung et al., 2008). Since LPS-
induced NO production by microglia involves all these intra-
cellular signaling pathways, we hypothesize that histamine may
also mediate NO production by some of these pathways. The
use of selective inhibitors of these pathways as well as the eval-
uation of their expression and activation may be helpful to dis-
close the signaling pathways involved in NO-mediated histamine
effects.
HISTAMINE: DUAL ROLE IN
NEUROPROTECTION/NEURODEGENERATION
The neuronal histaminergic system is involved in many phys-
iological functions and consequently severely affected in age-
related neurodegenerative diseases. The production of neuronal
histamine shows diurnal fluctuations in control patients who had
no neuropsychiatric disorders, while this fluctuation was strongly
altered in patients with neurodegenerative diseases (Shan et al.,
2013). Moreover, altered levels of histamine found in the diseased
brain and in the peripheral system may modulate both the innate
and adaptive immune responses ultimately affecting neuronal
survival. Brain diseases in which the histaminergic system may be
involved include MS, PD, Alzheimer’s disease (AD), among others
(Figure 1).
MS is characterized by focal lymphocytic infiltrations to the
brain leading to damage of myelin and axons. Initially, the
inflammatory response is transient and remyelination occurs, but
over time widespread microglial activation ensues along with
extensive and chronic neurodegeneration (Passani and Ballerini,
2012). The observation that histamine may be implicated in MS
dates back to the early 1980s when Tuomisto et al. reported that
patients with remitting or progressive disease showed histamine
levels about 60% higher than controls, suggesting an altered
histamine metabolism in MS (Tuomisto et al., 1983). However,
another clinical study did not show elevated concentrations of
histamine and its metabolite methylhistamine in MS patients
when compared, in this case, with individuals affected by other
neurological diseases (Rozniecki et al., 1995). More recently, gene-
microarray analysis has shown that H1R expression is upreg-
ulated in MS lesions (Lock et al., 2002), and epidemiological
studies suggest a protective effect of brain penetrating H1R
antagonists (Alonso et al., 2006). Furthermore, in a small pilot
study, a cohort of MS patients treated with an H1R antagonist
showed signs of neurological amelioration (Logothetis et al.,
2005). The H1R has long been associated with inflammatory
responses and H1R antagonists may be used in brain repair
therapies.
The role histamine in AD is also well documented. How-
ever, contradictory data exists regarding the quantification of
histamine levels in brain compartments of AD patients, mak-
ing difficult a direct correlation between histaminergic neuro-
transmission and AD pathology (Brioni et al., 2011). Increased
histamine levels have been reported not only in the frontal cor-
tex, basal ganglia and hippocampus, but also, together with its
metabolites, in the CSF and serum of AD patients (Fernandez-
Novoa and Cacabelos, 2001). On the contrary to the above
findings, several other studies show decline in histamine levels
in AD brains. Recent studies show that H3R antagonists may
be efficient in AD therapy. Nathan et al. demonstrated that
GSK239512, a selective H3R antagonist, displayed a satisfactory
level of tolerability in AD patients with evidence of positive effects
on attention and memory (Nathan et al., 2013). Others studies
also support that H3R antagonists/inverse agonists are potentially
novel therapeutic targets for other diseases, such as vigilance and
sleep-wake disorders (Parmentier et al., 2007) and schizophrenia
(Vohora and Bhowmik, 2012).
Several abnormalities in the histaminergic system were also
found in PD patients. In post-mortem brain of PD patients, it
has been reported a dramatic increase of histaminergic inner-
vations, enlarged axonal innervations (Anichtchik et al., 2000a)
and increased histamine levels (Nuutinen and Panula, 2011),
while animal studies showed that increased endogenous his-
tamine levels may accelerate degeneration of SN dopaminer-
gic neurons in 6-hydroxydopamine (OHDA) lesioned rats (Liu
et al., 2007). In addition, increased mRNA levels of histamine
methyltransferase (HMT), a key enzyme involved in histamine
metabolism, were found in the SN and in the putamen of
PD patients (Shan et al., 2012). This increase may act as a
protective mechanism by metabolizing enhanced histamine lev-
els in these brain regions. Moreover, a Thr105Ile polymor-
phism of HMT was shown to be associated with PD (Palada
et al., 2012). Regarding the expression of histamine recep-
tors, it has been shown that H3R mRNA was significantly
decreased in the SN, while H4R mRNA expression showed a
significant increase in caudate nucleus and putamen in PD
patients (Shan et al., 2012). Vizuete et al. showed that the
SN dopaminergic neurons are highly sensitive to histamine-
induced neurotoxicity (Vizuete et al., 2000). Altogether, these
data suggest that histamine and its receptors may play an impor-
tant role in PD pathogenesis. However, it is still unclear how
microglia activation induced by histamine may contribute to
dopaminergic neuronal survival. Thus, we aimed to uncover
whether soluble factors released by microglia previously stim-
ulated with histamine or LPS could modulate dopaminergic
neuronal survival. LPS per se does not seem to have a direct
effect on neuronal viability making it an excellent tool to study
inflammation-mediated dopaminergic neurodegeneration (Block
et al., 2007). In our study, dopaminergic neuronal viability
was assessed by counting the numbers of tyrosine hydroxylase
(TH+)-immunoreactive neurons (using monoclonal mouse anti-
TH; 1:100 dilution; Transduction Laboratories), counterstained
with MAP2 (using polyclonal rabbit anti-MAP2; 1:200 dilution;
Santa Cruz Biotechnologies), on neuron-astrocyte midbrain co-
cultures from neonatal rats. The midbrain cultures were obtained
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from Wistar pregnant females with 15–16 gestational days and
were grown in Neurobasal medium supplemented with 2% B27,
25 µM/mL glutamate, 0.5/mL glutamine and 120 µg/mL gen-
tamicine for 5–6 days as described in Campos et al. (2012).
Conditioned medium derived from untreated microglial cells
were considered as the control condition and the resulting
values were set to 100%. As shown in Figures 2D and 2E,
the conditioned media derived from microglial cells pre-treated
for 24 h with 100 µM histamine or 100 ng/mL LPS induced
a 30% reduction in the number of TH+ cells (meanH100 =
69.2 ± 4.3; meanLPS = 68.5 ± 1.5; n = 4; dark gray bars).
To ensure that this effect was solely dependent on soluble fac-
tors released by microglial cells, we then incubated midbrain
neuronal cultures with culture media pre-treated for 24 h with
LPS or histamine, at 37◦C, but in the absence of microglial
cells. We found that the dopaminergic neuronal survival was
not affected when midbrain neuronal cultures were treated
with conditioned medium devoid of microglia-released factors
(meanH100 = 123.2 ± 28.5; meanLPS = 115.5 ± 18.4; n = 3;
Figure 2D; light gray bars). Herein we showed, for the first
time, that histamine promotes the release of toxic inflammatory
factors, including NO, by microglial cells, which can be capable
of damaging dopaminergic neurons. With this work we open a
new perspective for the therapeutic use of histamine and his-
tamine receptor antagonists to treat or ameliorate inflammation-
associated processes of neurodegenerative diseases, like those seen
in PD.
FUTURE PERSPECTIVES
Accumulating clinical and experimental evidences show that
changes in the histaminergic system may be associated with
the pathogenesis and progression of several neurodegenerative
diseases, including PD. We showed that histamine boosts neuroin-
flammation by promoting microglia migration and the release of
cytokines and NO. We also showed that production of neurotoxic
and inflammatory mediators by microglial cells upon histamine
stimulation leads to dopaminergic neurodegeneration. Based on
these data we may infer that microglia activation induced by
histamine may contribute to PD pathology, and may thus provide
a rationale for possible novel therapeutic strategies. We suggest
that the therapeutic use of histamine receptors antagonists may
be of great value to treat or ameliorate CNS pathologies or
neurodegenerative disorders which are commonly accompanied
by inflammation. Therefore, the following steps urge a better
understanding of the involvement of histamine and its receptors
in the modulation of microglial activation and subsequent neu-
ronal survival.
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